On February 24, the DEA issued a proposed rule on the remote prescribing of controlled substances, including buprenorphine, after the COVID-19 public health emergency ends. Healthcare providers and telemedicine groups are concerned that the proposed restrictions are unnecessarily restrictive and impose a public health crisis for those needing access to behavioral health treatment.
"Lack of access to buprenorphine is a bigger threat to public health than the threat of buprenorphine diversion." - ASAM President-elect, Dr. Brian Hurley
Read more from STAT news
DEA is accepting public comments on the proposed rule until 11:59 pm on March 28. When commenting, refer to “Docket No. DEA-407” on all correspondence, including attachments.
Click here to comment by 3/28
For guidance on commenting as well as an overview with FAQs on the DEA proposed rule: A legal guide for practitioners, policymakers, and telemedicine companies
-The MACS Team